|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thun MJ, Hannan LM, Adams-Campbell LL,
Boffetta P, Buring JE, Feskanich D, Flanders WD, Jee SH, Katanoda
K, Kolonel LN, et al: Lung cancer occurrence in never-smokers: An
analysis of 13 cohorts and 22 cancer registry studies. PLoS Med.
5:e1852008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Klein F, Amin Kotb WF and Petersen I:
Incidence of human papilloma virus in lung cancer. Lung Cancer.
65:13–18. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yanagawa N, Wang A, Kohler D, Santos Gda
C, Sykes J, Xu J, Pintilie M and Tsao MS: Human papilloma virus
genome is rare in North American non-small cell lung carcinoma
patients. Lung Cancer. 79:215–220. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sagerup CM, Nymoen DA, Halvorsen AR,
Lund-Iversen M, Helland A and Brustugun OT: Human papilloma virus
detection and typing in 334 lung cancer patients. Acta Oncol.
53:952–957. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sarchianaki E, Derdas SP, Ntaoukakis M,
Vakonaki E, Lagoudaki ED, Lasithiotaki I, Sarchianaki A,
Koutsopoulos A, Symvoulakis EK, Spandidos DA, et al: Detection and
genotype analysis of human papillomavirus in non-small cell lung
cancer patients. Tumour Biol. 35:3203–3209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Anantharaman D, Gheit T, Waterboer T,
Halec G, Carreira C, Abedi-Ardekani B, McKay-Chopin S, Zaridze D,
Mukeria A, Szeszenia-Dabrowska N, et al: No causal association
identified for human papillomavirus infections in lung cancer.
Cancer Res. 74:3525–3534. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Simen-Kapeu A, Surcel HM, Koskela P,
Pukkala E and Lehtinen M: Lack of association between human
papillomavirus type 16 and 18 infections and female lung cancer.
Cancer Epidemiol Biomarkers Prev. 19:1879–1881. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hasegawa Y, Ando M, Kubo A, Isa S,
Yamamoto S, Tsujino K, Kurata T, Ou SH, Takada M and Kawaguchi T:
Human papilloma virus in non-small cell lung cancer in never
smokers: A systematic review of the literature. Lung Cancer.
83:8–13. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Baba M, Castillo A, Koriyama C, Yanagi M,
Matsumoto H, Natsugoe S, Shuyama KY, Khan N, Higashi M, Itoh T, et
al: Human papillomavirus is frequently detected in
gefitinib-responsive lung adenocarcinomas. Oncol Rep. 23:1085–1092.
2010.PubMed/NCBI
|
|
11
|
Tung MC, Wu HH, Cheng YW, Wang L, Chen CY,
Yeh SD, Wu TC and Lee H: Association of epidermal growth factor
receptor mutations with human papillomavirus 16/18 E6 oncoprotein
expression in non-small cell lung cancer. Cancer. 119:3367–3376.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kato T, Koriyama C, Khan N, Samukawa T,
Yanagi M, Hamada T, Yokomakura N, Otsuka T, Inoue H, Sato M, et al:
EGFR mutations and human papillomavirus in lung cancer. Lung
Cancer. 78:144–147. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wood DE, Kazerooni E, Baum SL, Dransfield
MT, Eapen GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar
R, et al: Lung cancer screening, version 1.2015: featured updates
to the NCCN guidelines. J Natl Compr Canc Netw. 13:23–34.
2015.PubMed/NCBI
|
|
14
|
Wei W, Shi Q, Guo F, Zhang BY, Chen C,
Zhang NS and Dong XP: The distribution of human papillomavirus in
tissues from patients with head and neck squamous cell carcinoma.
Oncol Rep. 28:1750–1756. 2012.PubMed/NCBI
|
|
15
|
Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang
JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, et al: Relative
abundance of EGFR mutations predicts benefit from gefitinib
treatment for advanced non-small-cell lung cancer. J Clin Oncol.
29:3316–3321. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Syrjänen K: Detection of human
papillomavirus in lung cancer: Systematic review and meta-analysis.
Anticancer Res. 32:3235–3250. 2012.PubMed/NCBI
|
|
17
|
Ragin C, Obikoya-Malomo M, Kim S, Chen Z,
Flores-Obando R, Gibbs D, Koriyama C, Aguayo F, Koshiol J, Caporaso
NE, et al: HPV-associated lung cancers: An international pooled
analysis. Carcinogenesis. 35:1267–1275. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang JL, Fang CL, Wang M, Yu MC, Bai KJ,
Lu PC and Liu HE: Human papillomavirus infections as a marker to
predict overall survival in lung adenocarcinoma. Int J Cancer.
134:65–71. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cheng YW, Chiou HL, Sheu GT, Hsieh LL,
Chen JT, Chen CY, Su JM and Lee H: The association of human
papillomavirus 16/18 infection with lung cancer among nonsmoking
Taiwanese women. Cancer Res. 61:2799–2803. 2001.PubMed/NCBI
|
|
20
|
Pallis AG and Syrigos KN: Lung cancer in
never smokers: Disease characteristics and risk factors. Crit Rev
Oncol Hematol. 88:494–503. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mitsudomi T, Kosaka T and Yatabe Y:
Biological and clinical implications of EGFR mutations in lung
cancer. Int J Clin Oncol. 11:190–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et
al: Clinical and biological features associated with epidermal
growth factor receptor gene mutations in lung cancers. J Natl
Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Paez JG, Janne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hsu NY, Cheng YW, Chan IP, Ho HC, Chen CY,
Hsu CP, Lin MH and Chou MC: Association between expression of human
papillomavirus 16/18 E6 oncoprotein and survival in patients with
stage I non-small cell lung cancer. Oncol Rep. 21:81–87.
2009.PubMed/NCBI
|
|
25
|
Márquez-Medina D, Gasol-Cudós A,
Taberner-Bonastre MT, Samamé Pérez-Vargas JC, Salud-Salvia A and
Llombart-Cussac A: Human papillomavirus in non-small-cell lung
cancer: The impact of EGFR mutations and the response to erlotinib.
Arch Bronconeumol. 49:79–81. 2013.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu HH, Wu JY, Cheng YW, Chen CY, Lee MC,
Goan YG and Lee H: cIAP2 upregulated by E6 oncoprotein via
epidermal growth factor receptor/phosphatidylinositol 3-kinase/AKT
pathway confers resistance to cisplatin in human papillomavirus
16/18-infected lung cancer. Clin Cancer Res. 16:5200–5210. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang E, Feng X, Liu F, Zhang P, Liang J
and Tang X: Roles of PI3K/Akt and c-Jun signaling pathways in human
papillomavirus type 16 oncoprotein-induced HIF-1α, VEGF, and IL-8
expression and in vitro angiogenesis in non-small cell lung cancer
cells. PLoS One. 9:e1034402014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sung WW and Lee H: The role of
interleukin-10 in the progression of human
papillomavirus-associated lung carcinoma. Oncoimmunology.
2:e258542013. View Article : Google Scholar : PubMed/NCBI
|
